MDxHealth (MDXH) Expected to Announce Earnings on Wednesday

Key Points

• MDxHealth is expected to announce its Q2 2025 earnings on August 20th, with analysts predicting a loss of <$0.13 per share and revenue of $26.31 million.
• The company recently reported earnings for the previous quarter, with an EPS of <$0.15, missing the estimate by $0.02, although revenue matched expectations.
• Analysts have varied opinions on MDxHealth, with Wall Street Zen upgrading its rating to "hold" while Craig Hallum initiated coverage with a "buy" rating and an $8.00 price target.

MDxHealth (NASDAQ:MDXH - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 20th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $26.31 million for the quarter. MDxHealth has set its Q2 2025 guidance at -0.150--0.150 EPS.

MDxHealth (NASDAQ:MDXH - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The firm had revenue of $26.60 million for the quarter, compared to analysts' expectations of $26.60 million. MDxHealth had a negative net margin of 34.98% and a negative return on equity of 274.67%. On average, analysts expect MDxHealth to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

MDxHealth Stock Up 0.4%

Shares of MDXH stock traded up $0.01 during mid-day trading on Friday, hitting $2.85. 87,150 shares of the stock traded hands, compared to its average volume of 85,143. The stock has a market cap of $134.78 million, a P/E ratio of -3.24 and a beta of 1.41. The stock's fifty day moving average is $2.31 and its two-hundred day moving average is $1.94. MDxHealth has a 52-week low of $1.35 and a 52-week high of $3.50. The company has a debt-to-equity ratio of 13.81, a current ratio of 2.00 and a quick ratio of 1.92.

Analyst Ratings Changes

Several equities analysts recently commented on MDXH shares. Craig Hallum started coverage on shares of MDxHealth in a research report on Thursday, July 17th. They issued a "buy" rating and a $8.00 price objective for the company. Wall Street Zen raised shares of MDxHealth to a "hold" rating in a research report on Saturday, May 24th.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.